RayzeBio inc (DELISTED) (RYZB:DL)
62.49
0.00 (0.00%)
USD |
NASDAQ |
Mar 06, 16:00
RayzeBio Cash from Financing (Quarterly): 314.84M for Sept. 30, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
Date | Value |
---|---|
September 30, 2023 | 314.84M |
Date | Value |
---|---|
September 30, 2022 | 157.90M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
157.90M
Minimum
Sep 2022
314.84M
Maximum
Sep 2023
236.36M
Average
236.36M
Median
Cash from Financing (Quarterly) Benchmarks
Bristol-Myers Squibb Co | 14.64B |
Karuna Therapeutics Inc (DELISTED) | 19.87M |
Ambrx Biopharma Inc (DELISTED) | 9.71M |
Pfizer Inc | -4.931B |
Mirati Therapeutics Inc (DELISTED) | 334.70M |
Cash from Financing (Quarterly) Related Metrics
Cash from Operations (Quarterly) | -45.26M |
Cash from Investing (Quarterly) | -146.77M |
Free Cash Flow Per Share (Quarterly) | -5.005 |